Regeneron Pharmaceuticals (REGN) Long-Term Debt Repayments (2009 - 2017)
Regeneron Pharmaceuticals' quarterly Long-Term Debt Repayments came in at -$25000.0 in Q4 2017, down 110.0% year-on-year from $250000.0 in Q4 2016, and down 100.35% quarter-over-quarter from $7.1 million in Q2 2017.
Regeneron Pharmaceuticals has reported Long-Term Debt Repayments for 9 years, with the latest figure at -$25000.0 in Q4 2017.
- For the quarter ending Q4 2017, Long-Term Debt Repayments fell 110.0% year-over-year to -$25000.0; the trailing twelve-month figure through Sep 2018 stood at -$25000.0 (down 100.12% YoY), and the FY2017 full-year result was $19.9 million, up 54.26% from the prior year.
- Long-Term Debt Repayments for Q4 2017 stood at -$25000.0, down from $7.1 million in the prior quarter.
- The five-year high for Long-Term Debt Repayments was $221.4 million in Q4 2014, with the low at -$3.6 million in Q4 2013.
- Average Long-Term Debt Repayments over 5 years is $17.4 million, with a median of $808500.0 recorded in 2013.
- Year-over-year, Long-Term Debt Repayments tumbled 706.15% in 2013 and jumped 6168.76% in 2014.
- Tracing REGN's Long-Term Debt Repayments over 5 years: stood at -$3.6 million in 2013, then jumped by 6168.76% to $221.4 million in 2014, then tumbled by 99.56% to $968000.0 in 2015, then sank by 74.17% to $250000.0 in 2016, then tumbled by 110.0% to -$25000.0 in 2017.
- The last three Long-Term Debt Repayments figures came in at -$25000.0 (Q4 2017), $7.1 million (Q2 2017), and $12.9 million (Q1 2017), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | -25,000.00 |
| Dec 31, 2017 | -25,000.00 |
| Jun 30, 2017 | 7.06 Mn |
| Jun 30, 2017 | 7.06 Mn |
| Mar 31, 2017 | 12.86 Mn |
| Mar 31, 2017 | 12.86 Mn |
| Dec 31, 2016 | 250,000.00 |
| Dec 31, 2016 | 250,000.00 |
| Sep 30, 2016 | 12.65 Mn |
| Sep 30, 2016 | 12.65 Mn |
| Dec 31, 2015 | 968,000.00 |
| Dec 31, 2015 | 968,000.00 |
| Sep 30, 2015 | -375,000.00 |
| Sep 30, 2015 | -375,000.00 |
| Jun 30, 2015 | 10.09 Mn |
| Jun 30, 2015 | 10.09 Mn |
| Mar 31, 2015 | 16.69 Mn |
| Mar 31, 2015 | 16.69 Mn |
| Dec 31, 2014 | 221.45 Mn |
| Dec 31, 2014 | 221.45 Mn |
| Sep 30, 2014 | -276,000.00 |
| Sep 30, 2014 | -276,000.00 |
| Jun 30, 2014 | -534,000.00 |
| Jun 30, 2014 | -534,000.00 |
| Dec 31, 2013 | -3.65 Mn |
| Dec 31, 2013 | -3.65 Mn |
| Sep 30, 2013 | 1.63 Mn |
| Sep 30, 2013 | 1.63 Mn |
| Jun 30, 2013 | -649,000.00 |
| Jun 30, 2013 | -649,000.00 |
| Mar 31, 2013 | 649,000.00 |
| Mar 31, 2013 | 649,000.00 |
| Dec 31, 2012 | 602,000.00 |
| Dec 31, 2012 | 602,000.00 |
| Sep 30, 2012 | 587,000.00 |
| Sep 30, 2012 | 587,000.00 |
| Jun 30, 2012 | 514,000.00 |
| Jun 30, 2012 | 514,000.00 |
| Mar 31, 2012 | 500,000.00 |
| Mar 31, 2012 | 500,000.00 |
| Dec 31, 2011 | 657,000.00 |
| Dec 31, 2011 | 657,000.00 |
| Sep 30, 2011 | 306,000.00 |
| Sep 30, 2011 | 306,000.00 |
| Jun 30, 2011 | 398,000.00 |
| Jun 30, 2011 | 398,000.00 |
| Mar 31, 2011 | 306,000.00 |
| Mar 31, 2011 | 306,000.00 |
| Dec 31, 2010 | 1.03 Mn |
| Dec 31, 2010 | 1.03 Mn |
| Jun 30, 2010 | 555,000.00 |
| Jun 30, 2010 | 555,000.00 |
| Mar 31, 2010 | -555,000.00 |
| Mar 31, 2010 | -555,000.00 |
| Dec 31, 2009 | -102,000.00 |
| Dec 31, 2009 | -102,000.00 |
| Sep 30, 2009 | -773,000.00 |
| Sep 30, 2009 | -773,000.00 |